WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018064851) USE OF LOW-DOSE SILDENAFIL AS ANTITUMOR DRUG
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/064851    International Application No.:    PCT/CN2016/103957
Publication Date: 12.04.2018 International Filing Date: 31.10.2016
IPC:
A61K 31/519 (2006.01), A61P 35/00 (2006.01)
Applicants: GUANGZHOU DAWNLIGHT BIOTECH COMPANY [CN/CN]; Room 426, No.81, The 2nd Donghui Street, Luogang District Guangzhou, Guangdong 510530 (CN)
Inventors: LIU, Yu; (CN)
Agent: GUANGZHOU TIANHE HENGHUA ZHIXIN PATENT AGENCY (GENERAL PARTNERSHIP); Room 1307, No.689, Tianhe North Road, Tianhe District Guangzhou, Guangdong 510633 (CN)
Priority Data:
201610884154.0 09.10.2016 CN
Title (EN) USE OF LOW-DOSE SILDENAFIL AS ANTITUMOR DRUG
(FR) UTILISATION DE SILDÉNAFIL À FAIBLE DOSE COMME MÉDICAMENT ANTITUMORAL
(ZH) 低剂量西地那非作为抗肿瘤药物的应用
Abstract: front page image
(EN)The invention discloses a use of low-dose sildenafil as an antitumor drug. The chemical name of the sildenafil is 1-[4-ethoxy-3-[5-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolol[4,3d]pyrimidin)]phenylsulfonyl]-4-methylpiperazin citrate, and a using dosage of the sildenafil is 2-25 mg. Sildenafil citrate with an oral dose of 2-25 mg, an injection dose of 2-10 mg or an external application dose lower than 1% by mass can be used for the treatment of malignant tumor.
(FR)L'invention concerne l'utilisation de sildénafil à faible dose comme médicament antitumoral. Le nom chimique du sildénafil est le 1-[4-éthoxy-3-[5-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolol[4,3d]pyrimidine)]phénylsulfonyl]-4-méthylpipérazine citrate, et la dose à laquelle le sildénafil est utilisé est comprise entre 2 et 25 mg. Le citrate de sildénafil, par voie orale à une dose comprise entre 2 et 25 mg, par injection à une dose comprise entre 2 et 10 mg, ou en application externe à une dose inférieure à 1 % en masse, peut être utilisé pour le traitement de tumeurs malignes.
(ZH)本发明提供一种低剂量西地那非作为抗肿瘤药物的应用,所述西地那非的化学名称为1-[4-乙氧基-3-[5-(6,7-二氢-1-甲基-7-氧代-3-丙基-1H-吡唑并[4,3d]嘧啶)]苯磺酰]-4-甲基哌嗪枸橼酸盐,所述西地那非的使用剂量为2~25mg。本发明以每天口服剂量2~25mg,或注射剂量2~10mg,或外用剂量质量百分比含量低于1%的西地那非枸橼酸盐,应用于恶性肿瘤的治疗。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)